Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

357 results about "Programmed death" patented technology

Programmed cell death. Programmed cell death (PCD) is the deliberate suicide of an unwanted cell in a multicellular organism. In contrast to necrosis, which is a form of cell death that results from acute tissue injury and provokes an inflammatory response, PCD is carried out in a regulated process that generally confers advantages...

Treatment of lung cancer using a combination of an Anti-PD-1 antibody and another Anti-cancer agent

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
Owner:BRISTOL MYERS SQUIBB CO

Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Owner:BRISTOL MYERS SQUIBB CO

Multi-modal prediction algorithm for esophageal cancer PD-L1 biomarker and immunotherapy response

The invention provides a brand new programmed death ligand 1 (PD-L1) level and immunotherapy response prediction algorithm based on the application of a deep learning technology in medical images in combination with methods of multi-modal feature fusion, a self-attention mechanism, adversarial learning and the like. The algorithm comprises the following steps of data preprocessing, encoder feature extraction, radiomics feature extraction, multi-modal feature fusion, PD-L1 level prediction and immunotherapy response prediction. According to the invention, the pathological image (Hamp; according to the method, a CT image (e.g., E staining section), a CT image and clinical data are integrated into a deep learning model for predicting the PD-L1 level of an esophageal squamous cell carcinoma (ESCC) patient. In addition, by extracting PD-L1 features of an immunotherapy patient, a model for predicting immunotherapy response is constructed. By fusing multi-modal data, auc of the model in a PD-L1 prediction task is equal to 0.835, auc of the model in an immunotherapy reaction task is equal to 0.806, a new thought and method are provided for related research in the field of tumor treatment, and beneficial reference is provided for clinical treatment.
Owner:NANJING TECH UNIV

Combination therapy for lung cancer

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.
Owner:BRISTOL MYERS SQUIBB CO

Application of MCU inhibitor in preparation of medicine for preventing or treating intestinal ischemia-reperfusion injury

The invention discloses application of an MCU (microprogrammed control unit) inhibitor in preparation of a medicine for preventing or treating intestinal ischemia-reperfusion injury, and relates to the technical field of biological medicine, and the MCU inhibitor comprises one or two of a reagent for inhibiting MCU gene expression and a reagent for inhibiting MCU protein activity. The MCU inhibitor disclosed by the invention is beneficial to relieving intestinal mucosa injury and inflammatory change of intestinal tissues, improving completeness of a villus structure, reducing pathological injury degree score of the intestinal tissues and relieving cell apoptosis degree in the intestinal tissues, so that the MCU inhibitor is beneficial to relieving programmed death of intestinal mucosa cells; as a main component, the pharmaceutical composition is beneficial for preventing or treating intestinal ischemia-reperfusion injury.
Owner:RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)

Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof

This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and / or PD-L1.
Owner:NOVIMMUNE SA

Construction method of anti-programmed death protein-1 monoclonal antibody treatment response prediction model

The invention provides a construction method of an anti-programmed death protein-1 monoclonal antibody treatment response prediction model, and belongs to the technical field of construction methods of prediction models. The method comprises the following steps: acquiring a blood sample of a non-small cell lung cancer patient; extracting peripheral blood mononuclear cells of the blood sample of the patient before and after the treatment of the anti-programmed death protein-1 monoclonal antibody; sequentially carrying out treatment through the steps of protein extraction, reductive alkylation and enzymolysis to obtain a sample peptide fragment; performing basic characteristic analysis and function annotation to obtain a protein spectrum and a modification spectrum of peripheral blood mononuclear cells of the non-small cell lung cancer patient treated by the anti-programmed death protein-1 monoclonal antibody; screening by utilizing machine learning to obtain a biomarker; and monitoring to obtain the anti-programmed death protein-1 monoclonal antibody treatment response prediction model. The method can be used for predicting the treatment effect of the anti-programmed death protein-1 monoclonal antibody of a non-small cell lung cancer patient.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

PD-1 monoclonal antibody and application thereof

The invention discloses a PD-1 (programmed death-1) monoclonal antibody and application thereof, the invention provides the monoclonal antibody, an antibody heavy chain complementarity determining region comprises CDR-H1, CDR-H2 and CDR-H3 which are respectively shown as SEQ ID NO.1-3, and an antibody light chain complementarity determining region comprises CDR-L1, CDR-L2 and CDR-L3 which are respectively shown as SEQ ID NO.4, LAS (LAS) and SEQ ID NO.5.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Treatment of lung cancer using a combination of an Anti-PD-1 antibody and an Anti-CTLA-4 antibody

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Owner:BRISTOL MYERS SQUIBB CO

Application of lactyltransferase inhibitor in pancreatic cancer and immunotherapy thereof

The invention relates to the technical field of cancer treatment, and provides application of a lactyltransferase inhibitor in pancreatic cancer and immunotherapy thereof. According to the present invention, the histone lactosyltransferase inhibitor and the anti-programmed death receptor-1 antibody are combined to form the composition for pancreatic cancer and immunotherapy thereof, such that the recognition and the removal of the immune system on the cancer cells can be enhanced, the growth of the pancreatic cancer tumor can be effectively inhibited, and the survival time of the pancreatic cancer patient can be prolonged. The histone lactosyltransferase inhibitor reduces the infiltration level of tumor-associated neutrophil, increases the infiltration level of CD8 positive T cells, reverses the composition of a pancreatic cancer inhibitory immune microenvironment, and generates a synergistic anti-tumor effect with an anti-programmed death receptor-1 antibody. The traditional Chinese medicine composition is suitable for early-stage, middle-stage and late-stage treatment of pancreatic cancer, improves the survival rate and the treatment effect of pancreatic cancer patients, remarkably reduces the side effects of treatment and improves the living quality of the pancreatic cancer patients.
Owner:南昌大学第一附属医院

Stable formulations of Anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof

The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.
Owner:MERCK SHARP & DOHME LLC

PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use

The present disclosure provides recombinantly manufactured fusion proteins comprising a Programmed Death-Ligand 1 (PD-L1) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients as a treatment for cancers, tumors or other diseases associated with expression of the PD-L1 protein in dogs. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.
Owner:AKSTON BIOSCIENCES CORP

Dual inhibitors of vista and PD-1 pathways

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as V-domain immunoglobulin suppressor of T-cell activation (VISTA) inhibitors or as dual inhibitors of VISTA and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA and its ligands, PD-1, PD-L1, and / or PD-L2.
Owner:AURIGENE ONCOLOGY LIMITED

Anti- programmed death-ligand 1 (PD-l1) antibody molecules, encoding polynucleotides, and methods of use

PendingUS20250145716A1Drug photocleavageAntibody ingredientsPhthalocyanine dyeProgrammed death
Provided herein are anti-Programmed Death-Ligand (PD-L1) antibodies, antigen-binding fragments thereof, multispecific antibodies and encoding polynucleotides. Also provided are PD-L1-targeted phthalocyanine dye conjugates, compositions and articles of manufacture containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the anti-PD-L1 antibodies, fragments, and conjugates specifically bind to human PD-L1. Among the anti-PD-L1 antibodies are human antibodies and humanized antibodies. Also provided are methods and uses employing the provided anti-PD-L1 antibodies, antigen-binding fragments, and conjugates such for treatment of human patients.
Owner:RAKUTEN MEDICAL INC

Methods of treating a tumor using an anti-PD-1 antibody

This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
Owner:BRISTOL MYERS SQUIBB CO

A composition comprising a combination of an anti-PD-1 antibody and another antibody

The present invention relates to a composition comprising a combination of an anti-PD-1 antibody and an additional antibody. Pharmaceutical compositions are provided, which comprise a combination of anticancer agents that are a first antibody and a second antibody. In some embodiments, the first antibody is an anti-programmed death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed-dose formulation. In certain embodiments, the composition is administered in an absolute dose. The present disclosure also provides a kit for treating a subject having a disease, the kit comprising a dose of any of the compositions disclosed herein and instructions for using the composition to treat a disease in any of the disclosed methods.
Owner:BRISTOL MYERS SQUIBB CO

Methods of treating urothelial carcinoma using an Anti-PD-1 antibody

This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Owner:BRISTOL MYERS SQUIBB CO

Gene OsCYP86A9 for regulating and controlling development of rice anther as well as encoding protein and application of gene OsCYP86A9

The invention relates to a gene OsCYP86A9 for regulating and controlling rice anther development as well as an encoding protein and application thereof. The amino acid sequence and the nucleotide sequence of the rice anther development regulation gene OsCYP86A9 are respectively shown as SEQ ID NO. 1 and SEQ ID NO. 2 or SEQ ID NO. 3. The gene OsCYP86A9 and the encoding protein thereof provided by the invention can be used for regulating and controlling the fertility and the maturing rate of the rice pollen: the phenotype of a gene knockout plant CR-1 is consistent with that of an EMS mutant oscy86a9, and the phenotype of the gene knockout plant CR-1 and the phenotype of the EMS mutant oscy86a9 both show that the maturing rate of ears is reduced, and part of pollen is aborted; the fertility of a mutant plant into which a genome complementary fragment is transferred is recovered, and the anther form, pollen staining and the maturing rate are not obviously different from those of a wild type; the mutation of the OsCYP86A9 affects the programmed death of the anther tapetum and the formation of the outer wall and the inner layer of the pollen.
Owner:SOUTH CHINA NORMAL UNIV +2

Methods of treating a tumor using an Anti-PD-1 antibody

This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
Owner:BRISTOL MYERS SQUIBB CO

LAG-3 antagonist therapy for hematological cancer

The disclosure provides a method of treating a human subject afflicted with a hematological cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor). In some aspects, the subject is greater than or equal to about 12 years old and has a weight of greater than or equal to about 40 kg, including subjects less than or equal to about 30 years old or less than about 18 years old. In some aspects, the subject has a weight of less than about 40 kg and / or is less than about 12 years old.
Owner:BRISTOL MYERS SQUIBB CO

Bispecific antibodies useful for gene therapy

The present disclosure provides bispecific antibodies useful in gene therapy. Specifically, the invention provides a bispecific antibody, and the bispecific antibody comprises a heavy chain variable region (VHVEGF) and a light chain variable region (VLVEGF) which are targeted to a vascular endothelial growth factor (VEGF), and a heavy chain variable region (VHPD-L1) and a light chain variable region (VLPD-L1) which are targeted to a programmed death receptor-ligand 1 (PD-L1). The bispecific antibody provided by the disclosure can be used for gene therapy, such as AAV or mRNA mediated gene therapy, and can effectively block PD-1 / PD-L1 and VEGF / VEGFR pathways, and inhibit tumors in vitro and in vivo.
Owner:HANGZHOU XINCHANG GENE THERAPEUTICS INC

Preparation method and application of diagnosis and treatment agent for tumor radiotherapy sensitization

The invention provides a preparation method and application of a diagnosis and treatment agent for tumor radiotherapy sensitization, and belongs to the field of pharmacy. According to the method, a one-pot method is innovatively adopted to load D-mannose and manganese-coated gold nanoparticles (Au (at) MnO2NPs) into ZIF-8 nanoparticles, and the nano diagnosis and treatment agent (Dman / Au (at) MnO2ZIF-8) for tumor radiotherapy sensitization is prepared. The prepared composite nano diagnosis and treatment agent is enriched in tumor tissues by enhancing permeation and retention effects, releases D-mannose, gold nanoparticles and Mn < 2 + > capable of generating T1 magnetic resonance (MR) imaging signals, and realizes tumor radiotherapy sensitization under the guidance of MR imaging. Besides, D-mannose can further increase the sensitivity of tumor cells to ionizing radiation by inducing protein degradation of a tumor cell programmed death receptor-ligand 1, so that a synergistic treatment effect is achieved, and a new thought is expected to be provided for integration of radiotherapy sensitization and diagnosis and treatment of tumors.
Owner:XUZHOU MEDICAL UNIVERSITY

Anti-PD1 antibodies and their use as therapeutics and diagnostics

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Owner:BEIGENE LTD

Stable high concentration arginine formulations containing PD-1 antibodies and methods of use thereof

The present invention relates generally to the field of pharmaceutical formulations of antibodies or antigen-binding fragments thereof directed against the human programmed death receptor PD-1. These formulations may further contain a formulation buffer, a viscosity reducer, and a nonionic surfactant. The pharmaceutical formulations of the invention exhibit a low viscosity and a comparable degree of antibody stability upon exposure to heat and other physical stresses. Methods of making such antibody formulations and methods of using such antibody formulations are also provided.
Owner:BEIGENE SWITZERLAND GMBH

Methods for early detection of cancer

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, including immune checkpoint regulators such as programmed death ligand 1 (PDL-1). Using methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at overcoming resistance mechanisms.
Owner:GUARDANT HEALTH INC

NBDHEX and PD-1 inhibitor combined anti-tumor medicine composition and application

The invention discloses an anti-tumor pharmaceutical composition based on NBDHEX and application of the anti-tumor pharmaceutical composition in treatment of immunosuppressive malignant tumors. The pharmaceutical composition comprises NBDHEX (6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio) hexanol) and a PD-1 (programmed death-1) inhibitor, and is characterized in that the NBDHEX (6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio) hexanol) and the PD-1 inhibitor are used as raw materials. The NBDHEX can induce tumor cells to generate immunogenic death and promote tumor antigen release, DAMPs signal activation and dendritic cell maturation, so that an immunosuppressive tumor microenvironment is remodeled, and CD8 + T cell infiltration and effector functions are enhanced. The pharmaceutical composition can significantly improve the anti-tumor immune response intensity and the treatment response rate. Animal experiments and cell experiments verify the synergistic anti-tumor effect of the composition in a lymphoma model. The immunosuppressive malignant tumors are suitable for treatment of various immunosuppressive malignant tumors including lymphoma, and are especially suitable for patients with poor single-drug reaction or drug resistance to immune checkpoint inhibitors, and a new way is provided for clinical treatment of tumors.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Treatment of renal cancer using a combination of an Anti-PD-1 antibody and another Anti-cancer agent

This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.
Owner:BRISTOL MYERS SQUIBB CO

Improved aluminum fluoride radiosynthesis of [18f]DK222

A method for preparing an 18F-labeled imaging agent comprising a conjugate of a peptide having a binding specificity for programmed death ligand 1 (PD-L1) and a chelating moiety, and optionally a linker. In representative aspects, the 18F-labeled imaging agent is [18F]-DK222.
Owner:JOHNS HOPKINS UNIVERSITY